What is Lexicon Pharmaceuticals's cumulative cost basis?

Lexicon Pharmaceuticals (LXRX) reported cumulative cost basis of $4.57M in Q1 2026.

How has Lexicon Pharmaceuticals's cumulative cost basis changed year-over-year?

Lexicon Pharmaceuticals's cumulative cost basis decreased by 0.0% year-over-year, from $4.57M to $4.57M.

What is the long-term trend for Lexicon Pharmaceuticals's cumulative cost basis?

Over 3 years (2020 to 2025), Lexicon Pharmaceuticals's cumulative cost basis has grown at a -9.2% compound annual growth rate (CAGR), from $6.11M to $4.57M.

Lexicon Pharmaceuticals LXRX Cumulative Cost Basis

Cumulative Cost Basis at other companies

Vertex PharmaceuticalsVRTX

——

Zevra Therapeutics, Inc.ZVRA

——

Esperion TherapeuticsESPR

——

Aurinia PharmaceuticalsAUPH

——

Ionis PharmaceuticalsIONS

——

AbbottABT

——

Other financials

Income statement

See full

Revenue$21.1M+1,572%

Gross profit$21.0M+1,604%

Operating income-$996.0K+96.1%

Net income-$1.0M+95.9%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$67.1M+6.7%

Total debt$57.7M-45.7%

Total equity$202.9M+64.9%

Total assets$268.8M-9.7%

Cash flow

See full

Operating cash flow-$14.7M+66.4%

CapEx--100%

Free cash flow-$17.2M+21.5%

Valuation

See full

Market cap$1.02B+273%

Enterprise value$1.01B+219%

P/S14.6×+5.9×

Profitability

See full

Gross margin99.5%+1.5pp

Operating margin-34.8%-16.8pp

Net margin-37.5%-18.1pp

FCF margin-578.5%-283pp

Returns & leverage

See full

Return on equity-16%-7.2pp

Debt / equity0.3×-0.6×

Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lexicon Pharmaceuticals's cumulative cost basis?: Lexicon Pharmaceuticals (LXRX) reported cumulative cost basis of $4.57M in Q1 2026.
How has Lexicon Pharmaceuticals's cumulative cost basis changed year-over-year?: Lexicon Pharmaceuticals's cumulative cost basis decreased by 0.0% year-over-year, from $4.57M to $4.57M.
What is the long-term trend for Lexicon Pharmaceuticals's cumulative cost basis?: Over 3 years (2020 to 2025), Lexicon Pharmaceuticals's cumulative cost basis has grown at a -9.2% compound annual growth rate (CAGR), from $6.11M to $4.57M.